Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 10/20 | 0.85 |
| ▸ | DRD3 | P35462 | 9/20 | 0.85 |
| ▸ | HTR1A | P08908 | 9/20 | 0.85 |
| ▸ | HRH1 | P35367 | 9/20 | 0.85 |
| ▸ | ADRA2A | P08913 | 8/20 | 0.85 |
| ▸ | SLC6A2 | P23975 | 8/20 | 0.85 |
| ▸ | ADRA1A | P35348 | 8/20 | 0.85 |
| ▸ | KCNH2 | Q12809 | 8/20 | 0.85 |
| ▸ | DRD1 | P21728 | 7/20 | 0.85 |
| ▸ | SLC6A3 | Q01959 | 7/20 | 0.85 |
| ▸ | ADRA2B | P18089 | 7/20 | 0.85 |
| ▸ | ADRA2C | P18825 | 7/20 | 0.85 |
| ▸ | HTR2A | P28223 | 7/20 | 0.85 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.85 |
| ▸ | CHRM1 | P11229 | 6/20 | 0.85 |
| ▸ | HTR2C | P28335 | 6/20 | 0.85 |
| ▸ | CHRM2 | P08172 | 5/20 | 0.85 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.85 |
| ▸ | CHRM3 | P20309 | 5/20 | 0.85 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.85 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Thioproperazine SCHEMBL29372322 | 0.92 | DRD3 (1.00) | DRD2DRD3HTR1AHRH1ADRA2A | |
| Thioproperazine SCHEMBL49902 | 0.92 | DRD3 (1.00) | DRD2DRD3HTR1AHRH1ADRA2A | |
| Thioproperazine SCHEMBL29394708 | 0.92 | DRD3 (1.00) | DRD2DRD3HTR1AHRH1ADRA2A | |
| SCHEMBL10136838 | 0.90 | DRD3 (0.85) | DRD2DRD3HTR1AHRH1ADRA2A | |
| SCHEMBL6946497 | 0.90 | DRD3 (0.85) | DRD2DRD3HTR1AHRH1ADRA2A | |
| SCHEMBL10136877 | 0.90 | DRD3 (0.85) | DRD2DRD3HTR1AHRH1ADRA2A | |
| Thioproperazine SCHEMBL3027811 | 0.88 | CYP3A4 (1.00) | DRD2DRD3HTR1AHRH1ADRA2A | |
| Thioproperazine SCHEMBL2386850 | 0.88 | CYP3A4 (1.00) | DRD2DRD3HTR1AHRH1ADRA2A | |
| Thioproperazine SCHEMBL29888916 | 0.88 | CYP3A4 (1.00) | DRD2DRD3HTR1AHRH1ADRA2A | |
| SCHEMBL10136823 | 0.88 | DRD3 (0.81) | DRD2DRD3HTR1AHRH1ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120035161-A1 | Novel Compositions and Methods of Treating Diseases Using the Same | CORRIDOR PHARMACEUTICALS, INC. | 2012-02-09 | — | — | US | disclosed |
| US-20120035161-A1 | Novel Compositions and Methods of Treating Diseases Using the Same | CORRIDOR PHARMACEUTICALS, INC. | 2012-02-09 | — | — | US | disclosed |
| US-7981885-B2 | N-[3-substituted piperazino] alkylphenothiazines; antiproliferative agents, apoptotic agents; 5-HT receptor antagonists | IMMUNE CONTROL INC. (US) | 2011-07-19 | — | — | US | disclosed |
| US-7981885-B2 | N-[3-substituted piperazino] alkylphenothiazines; antiproliferative agents, apoptotic agents; 5-HT receptor antagonists | IMMUNE CONTROL INC. (US) | 2011-07-19 | — | — | US | disclosed |
| US-7923445-B2 | 10-{3-[4-(2-Amino)ethylpiperazinyl]propyl}2-trifluoromethylphenothiazine and analogues and derivatives; antiproliferative agents; serotonin receptor antagonists; apoptosis in activated lymphocytes, including T, B, and and mylenoma cells; asthma; antiarthritic agents; rheumatic diseeases | IMMUNE CONTROL, INC. (US) | 2011-04-12 | — | — | US | disclosed |
| US-7923445-B2 | 10-{3-[4-(2-Amino)ethylpiperazinyl]propyl}2-trifluoromethylphenothiazine and analogues and derivatives; antiproliferative agents; serotonin receptor antagonists; apoptosis in activated lymphocytes, including T, B, and and mylenoma cells; asthma; antiarthritic agents; rheumatic diseeases | IMMUNE CONTROL, INC. (US) | 2011-04-12 | — | — | US | disclosed |
| US-20100130457-A1 | Phenothiazine Derivatives for Treatment of Asthma | IMMUNE CONTROL, INC. | 2010-05-27 | — | — | US | disclosed |
| US-20100130457-A1 | Phenothiazine Derivatives for Treatment of Asthma | IMMUNE CONTROL, INC. | 2010-05-27 | — | — | US | disclosed |
| US-20100035858-A1 | Novel Compositions and Methods for Binding and Inhibiting 5-HT4 Receptor | IMMUNE CONTROL, INC. | 2010-02-11 | — | — | US | disclosed |
| US-20100035858-A1 | Novel Compositions and Methods for Binding and Inhibiting 5-HT4 Receptor | IMMUNE CONTROL, INC. | 2010-02-11 | — | — | US | disclosed |
| US-20080132697-A1 | Novel compositions for treatment of diseases related to activated lymphocytes | IMMUNE CONTROL, INC. (US) | 2008-06-05 | — | — | US | disclosed |
| US-20080132697-A1 | Novel compositions for treatment of diseases related to activated lymphocytes | IMMUNE CONTROL, INC. (US) | 2008-06-05 | — | — | US | disclosed |
| US-20080125415-A1 | Novel methods for treatment of diseases related to activated lymphocytes | IMMUNE CONTROL, INC. (US) | 2008-05-29 | — | — | US | disclosed |
| US-20080125415-A1 | Novel methods for treatment of diseases related to activated lymphocytes | IMMUNE CONTROL, INC. (US) | 2008-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130457-A1 | Phenothiazine Derivatives for Treatment of Asthma | IL5, HRH4, TLR5 | DRD2 1397/4885DRD3 1798/4885HTR1A 345/4885 |
| US-20100035858-A1 | Novel Compositions and Methods for Binding and Inhibiting 5-HT4 Receptor | HTR4, HTR3B, HTR5A | DRD2 254/4885DRD3 356/4885HTR1A 6/4885 |
| US-20080132697-A1 | Novel compositions for treatment of diseases related to activated lymphocytes | NFATC1, CD4, TPH1 | DRD2 402/4885DRD3 664/4885HTR1A 6/4885 |
| US-20120035161-A1 | Novel Compositions and Methods of Treating Diseases Using the Same | NFATC1, BAX, BCL2 | DRD2 4807/4885DRD3 4778/4885HTR1A 3332/4885 |
| US-20080125415-A1 | Novel methods for treatment of diseases related to activated lymphocytes | HTR5A, TPH1, TPH2 | DRD2 358/4885DRD3 468/4885HTR1A 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.